<DOC>
	<DOCNO>NCT01100606</DOCNO>
	<brief_summary>A study determine safety , effectiveness , acceptability 2 method administration EUR-1008 ( APT-1008 ) ( Zenpep速 [ pancrelipase ] delay release capsule ) 3,000 lipase unit capsule , pancreatic enzyme product ( PEP ) , infant exocrine pancreatic insufficiency ( EPI ) due cystic fibrosis ( CF ) . This study sponsor Aptalis Pharma ( formerly Eurand ) .</brief_summary>
	<brief_title>A Study Evaluate Mode Administration Safety EUR-1008 ( APT-1008 ) Infants 1 12 Months Age</brief_title>
	<detailed_description>This multicenter , randomize , open-label , crossover study pediatric participant EPI due CF . The study carry infant 1 12 month age . The study comprise screen period ( 10 day ) follow 2 treatment period ( 10 day ) . During screen period , participant administer Zenpep速 5,000 ( pancrelipase ) mix small amount apple sauce . Once determine eligible participation , participant randomize 1 2 treatment sequence . Each sequence correspond take one treatment first period treatment second period , administer EUR-1008 ( APT-1008 ) ( Zenpep速 [ pancrelipase ] delay release capsule ) 3,000 lipase unit capsule either mixed apple juice use syringe nurser apple sauce use spoon .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Participants diagnosis CF base follow criterion : one clinical feature consistent CF , either genotype 2 identifiable mutation know cause CF sweat chloride concentration great 60 milliequivalent per liter quantitative pilocarpine iontophoresis Participants need PEP define monoclonal fecal elastase le 200 microgram per gram ( mcg/g ) stool Caregiver must willing switch participant previous PEP ( ) Zenpep速 Participants height weight ratio target great tenth percentile Participants clinically stable evidence concomitant illness acute upper low respiratory tract infection 7day interval prior screen precede accession clinical study Participants le 1 month old great 12 month old Participants history meconium ileus small bowel atresia newborn period require surgery Participants allergic pork porcine PEPs Participants respiratory condition serious comorbidity ( example patent ductus arteriosus [ PDA ] , necrotizing enterocolitis [ NEC ] ) investigator 's opinion would result intervention require hospitalization intensive pulmonary treatment trial Participants comorbidities independent CF , investigator 's opinion , would result inability participate study excess risk participant standard care Participants acute respiratory infection previous 14 day require antibiotic Participants require change antacid dose 7 day screen Participants administration oral , intramuscular ( IM ) , intravenous ( IV ) glucocorticoids 4 week prior screen Participants condition would , investigator 's opinion , limit participant 's ability complete study Participants currently participate participate investigational study , exception observational study , within 30 day screen visit</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Infants CF</keyword>
</DOC>